Loading...
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
Approval of an anti-CD20 chimeric monoclonal antibody, rituximab, has revolutionized cancer treatment and also validated CD20 targeting for providing benefit and improvement of overall response rate in B cell malignancies. Although many patients have benefited from the treatment of rituximab, there...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2828574/ https://ncbi.nlm.nih.gov/pubmed/20081379 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|